BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Su J, Lai J, Yang R, Xu B, Zhu Y, Zhao M, Yang C, Liang G. Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women. BMC Gastroenterol 2019;19:17. [PMID: 30683047 DOI: 10.1186/s12876-018-0916-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Pouya FD, Rasmi Y, Camci IY, Tutar Y, Nemati M. Performance of capecitabine in novel combination therapies in colorectal cancer. J Chemother 2021;:1-15. [PMID: 34019782 DOI: 10.1080/1120009X.2021.1920247] [Reference Citation Analysis]
2 Fu X, Zhang Y, Chang L, Hui D, Jia R, Liu N, Zhang H, Han G, Han Z, Li Y, Liu H, Zhu H, Li Q. The JPJDF has Synergistic Effect with Fluoropyrimidine in the Maintenance Therapy for Metastatic Colorectal Cancer. PRA 2020;15:257-69. [DOI: 10.2174/1574892815666200717141205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Huang W, Zhang H, Tian Y, Cha Y, Xiong H, Yuan X. Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS-mutant metastatic colorectal cancer. J Clin Pharm Ther 2022. [PMID: 35218209 DOI: 10.1111/jcpt.13576] [Reference Citation Analysis]
4 Zhao C, Pan Y, Wang Y, Li Y, Han W, Lu L, Tang W, Li P, Ou Z, Zhang M, Xiong Z, Xu R, Lu Q, Xu Z, Qi L, Wang L, Xu G. A novel cell-free single-molecule unique primer extension resequencing (cf-SUPER) technology for bladder cancer non-invasive detection in urine. Transl Androl Urol 2020;9:1222-31. [PMID: 32676405 DOI: 10.21037/tau-19-774] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]